ClinicalTrials.gg
CompletedNCT00424476BLISS-52Updated Dec 12, 2016Results posted

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 3 interventional study of Placebo and Belimumab 1 mg/kg in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc.. Completed at 92 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-12.

Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
865
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
2nd of 36
865 · median 81
Started
2007
the only one that year
Phase 3
11 of 36
none open now
Registered
3rd of 36
by date
Lead sponsor
6 of 36
Human Genome Sciences Inc.

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 11 in phase 3, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Autoimmune Diseases
  • Lupus
  • SLE
  • Systemic Lupus Erythematosus
  • Belimumab
  • Antibodies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of SLE by ACR criteria.
  • Active SLE disease.
  • Autoantibody-positive.
  • On stable SLE treatment regimen.

Key Exclusion Criteria:

  • Pregnant or nursing
  • Have received treatment with any B cell targeted therapy.
  • Have received treatment with a biological agent in the past year.
  • Have received IV cyclophosphamide within 180 days of Day 0.
  • Have severe lupus kidney disease.
  • Have active central nervous system (CNS) lupus.
  • Have required management of acute or chronic infections within the past 60 days.
  • Have current drug or alcohol abuse or dependence.
  • Have a historically positive test or test positive at screening for , , or .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
865 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Belimumab 1 mg/kg

    Belimumab 1 mg/kg

    Drug: Belimumab 1 mg/kg

  • Experimental
    Belimumab 10 mg/kg

    Belimumab 10 mg/kg

    Drug: Belimumab 10 mg/kg

Interventions

  • DrugPlacebo

    Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.

  • DrugBelimumab 1 mg/kg

    Drug page: Belimumab

    Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.

    Also known as: BENLYSTA™ (formerly LymphoStat-B™)

  • DrugBelimumab 10 mg/kg

    Drug page: Belimumab

    Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.

    Also known as: BENLYSTA™ (formerly LymphoStat-B™)

06

What researchers measure

Primary outcomes

  1. SLE Responder Index (SRI) Response Rate at Week 52

    Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline. SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.

    Time frame: Baseline, 52 weeks

  2. Mean Change in Physician's Global Assessment (PGA) at Wk 24.

    The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.

    Time frame: Baseline, 24 weeks

  3. Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.

    The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.

    Time frame: Baseline, 24 weeks

  4. Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52

    Time frame: Baseline, Weeks 40 through 52

Other outcomes

  1. Adverse Events (AE) Overview

    SEE ALSO ADVERSE EVENTS RESULTS SECTION

    Time frame: Up to 56 Weeks

07

Results

Posted May 5, 2011

Participant flow

Participant flow — Overall Study
MilestonePlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Started287288290
Completed226240241
Not completed614849
Withdrew: Withdrawal by subject763
Withdrew: Adverse event191615
Withdrew: Lack of efficacy161212
Withdrew: Lack of compliance111
Withdrew: Lost to follow-up463
Withdrew: Protocol violation723
Withdrew: Physician decision323
Withdrew: Other439

Outcome measures

PrimarySLE Responder Index (SRI) Response Rate at Week 52

Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline. SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).

Time frame:
Baseline, 52 weeks
Reported as:
Number · Percentage of participants
SLE Responder Index (SRI) Response Rate at Week 52
Percentage of participantsPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
SLE Responder Index (SRI) Response Rate at Week 5243.651.457.6
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0006 (For the primary analysis of the primary efficacy endpoint, a step-down sequential testing procedure was used to control the type 1 error.) · Odds ratio (or): 1.83 · 95% CI 1.30 to 2.59Adjusted for baseline stratification factors (SELENA SLEDAI Score: ≤9 vs ≥10; proteinuria: \<2g vs ≥2g per 24hr; Race: African/indig-American vs Other)
  • Placebo vs Belimumab 1 mg/kg · Regression, Logistic · p = 0.0129 (After superiority of 10 mg/kg vs placebo was established, the 1 mg/kg group was tested vs placebo (2-sided alpha=0.05).) · Odds ratio (or): 1.55 · 95% CI 1.10 to 2.19Adjusted for baseline stratification factors.
SecondaryPercent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.
Time frame:
Baseline, 52 weeks
Reported as:
Number · Percentage of participants
Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.
Percentage of participantsPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.46.053.158.3
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0024 · Odds ratio (or): 1.71 · 95% CI 1.21 to 2.41Adjusted for baseline stratification factors.
  • Placebo vs Belimumab 1 mg/kg · Regression, Logistic · p = 0.0189 · Odds ratio (or): 1.51 · 95% CI 1.07 to 2.14Adjusted for baseline stratification factors.
SecondaryMean Change in Physician's Global Assessment (PGA) at Wk 24.

The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · Scores on a 3-point scale
Mean Change in Physician's Global Assessment (PGA) at Wk 24.
Scores on a 3-point scalePlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Mean Change in Physician's Global Assessment (PGA) at Wk 24.-0.39 ± 0.03-0.44 ± 0.03-0.54 ± 0.03
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · ANCOVA · p = 0.0003Adjusted for baseline PGA score and baseline stratification factors.
  • Placebo vs Belimumab 1 mg/kg · ANCOVA · p = 0.2712Adjusted for baseline PGA score and baseline stratification factors.
SecondaryMean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.

The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.
Scores on a scalePlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.3.64 ± 0.423.65 ± 0.433.58 ± 0.46
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · ANCOVA · p = 0.8870Adjusted for the baseline PCS score and baseline stratification factors.
  • Placebo vs Belimumab 1 mg/kg · ANCOVA · p = 0.8127Adjusted for the baseline PCS score and baseline stratification factors.
SecondaryPercent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52
Time frame:
Baseline, Weeks 40 through 52
Reported as:
Number · Percentage of participants
Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52
Percentage of participantsPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 5212.0 (0 to 0)20.6 (1.08 to 3.31)18.6 (0.99 to 3.08)
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0526 · Odds ratio (or): 1.75 · 95% CI 0.99 to 3.08Adjusted for baseline prednisone dose level and baseline stratification factors.
  • Placebo vs Belimumab 1 mg/kg · Regression, Logistic · p = 0.0252 · Odds ratio (or): 1.89 · 95% CI 1.08 to 3.31Adjusted for baseline prednisone dose level and baseline stratification factors.
Other pre-specifiedAdverse Events (AE) Overview

SEE ALSO ADVERSE EVENTS RESULTS SECTION

Time frame:
Up to 56 Weeks
Reported as:
Number · Percentage of participants
Adverse Events (AE) Overview
Percentage of participantsPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
Percent of patients with at least 1 AE91.691.791.7
Percent of patients with at least 1 Serious AE12.516.314.1
Percent of patients with an AE resulting in death1.00.71.4

Adverse events

Collected over Up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—36/287 (12.5%)222/287 (77.4%)
Belimumab 1 mg/kg—47/288 (16.3%)219/288 (76%)
Belimumab 10 mg/kg—41/290 (14.1%)223/290 (76.9%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
PneumoniaInfections and infestations5/2871/2881/290
PyrexiaGeneral disorders1/2874/2884/290
CellulitisInfections and infestations1/2874/2881/290
Urinary tract infectionInfections and infestations2/2874/2882/290
OsteonecrosisMusculoskeletal and connective tissue disorders0/2873/2881/290
Lupus nephritisRenal and urinary disorders0/2873/2883/290
SLE arthritisMusculoskeletal and connective tissue disorders1/2870/2883/290
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2871/2883/290
Gastroenteritis bacterialInfections and infestations2/2870/2880/290
Herpes zosterInfections and infestations2/2872/2881/290
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlaceboBelimumab 1 mg/kgBelimumab 10 mg/kg
HeadacheNervous system disorders75/28758/28866/290
Upper respiratory tract infectionInfections and infestations47/28741/28836/290
ArthralgiaMusculoskeletal and connective tissue disorders33/28721/28832/290
InfluenzaInfections and infestations25/28722/28833/290
NauseaGastrointestinal disorders31/28716/28823/290
HypertensionVascular disorders30/28724/28817/290
NasopharyngitisInfections and infestations23/28730/28820/290
DiarrhoeaGastrointestinal disorders19/28728/28830/290
Urinary tract infectionInfections and infestations24/28727/28826/290
Back painMusculoskeletal and connective tissue disorders25/28725/28819/290

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBelimumab 1 mg/kgBelimumab 10 mg/kgTotal
Mean36.2 ± 11.835.0 ± 10.635.4 ± 10.835.5 ± 11.1
Age, Customized
Age, Customized(participants)PlaceboBelimumab 1 mg/kgBelimumab 10 mg/kgTotal
≤ 45 years225236236697
Between 45 and 65 years574852157
≥ 65 years54211
Gender
Gender(Participants)PlaceboBelimumab 1 mg/kgBelimumab 10 mg/kgTotal
Female270271280821
Male17171044
Region of Enrollment
Region of Enrollment(participants)PlaceboBelimumab 1 mg/kgBelimumab 10 mg/kgTotal
Europe33343198
South America145143140428
Southeast Asia103106115324
Australia65415
08

Study locations

92 sites
  • Hospital Britanico de Buenos Aires
    Buenos Aires, C1280AEB, Argentina
  • Centro Privado de Medicina Familiar
    Buenos Aires, C1417EYG, Argentina
  • Hospital Sirio Libanes
    Buenos Aires, C1419AHN, Argentina
  • Atencion Integral en Reumatologia
    Buenos Aires, C1426AAL, Argentina
  • Instituto de Investigaciones Medicas
    Buenos Aires, C1427ARO, Argentina
  • OMI, Organización Médica de Investigación
    Ciudad Autonoma de Buenos Aires, C1015ABO, Argentina
  • CIER, Centro de Investigaciones en Enfermedades Reumáticas
    Ciudad Autonoma de Buenos Aires, C1055AAF, Argentina
  • Hospital General de Agudos Carlos G. Durand
    Ciudad Autonoma de Buenos Aires, C1405DCS, Argentina
  • Hospital Interzonal General San Martín
    La Plata, B1904CFH, Argentina
  • CAICI, Instituto Centralizado de Asistencia e Investigación Clínica Integral
    Rosario, S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, T4000AXL, Argentina
  • Repatriation Hospital
    Daw Park, 5041, Australia
  • Emeritus Research, Cabrini Hospital
    Melbourne, 3144, Australia
  • Monash Medical Centre
    Melbourne, 3168, Australia
  • Royal Perth Hospital
    Shenton Park, 6008, Australia
  • Hospital de Clínicas - UNICAMP
    Campinas, 13083-888, Brazil
  • Hospital das Clínicas - Universidade do Paraná
    Curitiba, 80060-240, Brazil
  • Hospital de Clínicas - Universidade Federal de Pernambuco
    Fortaleza, 50670-901, Brazil
  • Hospital Geral de Goiânia
    Goiânia, 74110-120, Brazil
  • Hospital Universitário - Universidade Federal de Juiz de Fora
    Juiz de Fora, 36010-570, Brazil
  • Hospital São Lucas da PUC-RS
    Porto Alegre, 90610-000, Brazil
  • Hospital Universitário Pedro Ernesto - UERJ
    Rio de Janeiro, 20551-030, Brazil
  • Hospital Unversitario Clementino Fraga Filho UFRJ
    Rio de Janeiro, 21941-913, Brazil
  • Hospital Santa Izabel
    Salvador, 40050-410, Brazil
  • Hospital Abreu Sodré
    São Paulo, 04027-000, Brazil
  • Hospital do Servidor Público Estadual de São Paulo - Francisco Morato de Oliveira
    São Paulo, 04039-901, Brazil
  • Hospital Heliópolis
    São Paulo, 04266-010, Brazil
  • Hospital Dr. Sotero del Rio
    Santiago, 8207257, Chile
  • Pontificia Universidad Católica de Chile
    Santiago, 8330033, Chile
  • Clínica Dávila
    Santiago, 8431657, Chile
  • Hospital Dr. Gustavo Fricke
    Viña del Mar, 2570017, Chile
  • Office of Dr. Guzman
    Bogota, Cundinamarca, Colombia
  • Fundación Oftalmologica de Santander Clinica Carlos Ardila Lulle
    Bucaramanga, Santander, Colombia
  • Centro de Reumatologia y Ortopedia
    Barranquilla, Colombia
  • Fundación Instituto de Reumatología Fernando Chalem
    Bogota, Colombia
  • Centrode de Investigaciones en Reumatologia Especialidades Medicas (CIREEH)
    Bogotá, Colombia
  • Riesgo de Fracturas
    Bogotá, Colombia
  • SERVIMED
    Bucaramanga, Colombia
  • Corporación para Investigaciones Biológicas (CIB)
    Medellín, Colombia
  • Office of Dr. Jose Molina
    Medellín, Colombia
  • Pamela Youde Nethersole Eastern Hospital
    Chai Wan, Hong Kong
  • Rheumatology Assessment and Treatment Center, Pok Oi Hospital
    Shatin, Hong Kong
  • Tuen Mun Hospital
    Tuen Mun, Hong Kong
  • St. John's Medical College Hospital
    Bangalore, 560 034, India
  • Krishna Institute of Medical Sciences
    Hyderabaad, 500 003, India
  • Nizam's Institute of Medical Sciences
    Hyderabaad, 500 082, India
  • Apollo Hospitals
    Hyderabad, 500 033, India
  • Chhatrapati Shahuji Maharaj Medical University
    Lucknow, 226018, India
  • King Edward Memorial (K.E.M.) Hospital
    Mumbai, 400 012, India
  • Kerala Institute of Medical Sciences
    Trivandrum, 695029, India
  • Kyungpook National Univesity Hospital
    Daegu, 700-721, Korea, Republic of
  • Eulji University Hospital
    Daejeon, 302-799, Korea, Republic of
  • Inha University Hospital
    Inchon, 400-711, Korea, Republic of
  • Dong-A University Hospital 3-1 (Dept. Rhuematology)
    Pusan, 602-715, Korea, Republic of
  • Pusan National University Hospital
    Pusan, 602-739, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • The Hospital for Rheumatic Diseases, Hanyang University Hospital
    Seoul, 133-792, Korea, Republic of
  • Catholic Universtigy of Korea, Kangnam St. Mary's Hospital
    Seoul, 137-701, Korea, Republic of
  • Catholic University, Yoido St. Mary's Hospital
    Seoul, 150-713, Korea, Republic of
  • Ajou University Hospital
    Suwon, 443-721, Korea, Republic of
  • Hospital Nacional Alberto Sabogal Sologuren ESSALUD
    Lima, Callao 2, Peru
  • Hospital Nacional Guillermo Almenara Irigoyen ESSALUD
    Lima, L 13, Peru
  • Clinica Ricardo Palma Anexo 9 - Javier Prado Este
    Lima, L 27, Peru
  • Instituto de Ginecología y Reproducción
    Lima, L 33, Peru
  • Chong Hua Hospital
    Cebu City, 6000, Philippines
  • Davao Medical Center
    Davao City, 8000, Philippines
  • University of Perpetual Help -Rizal
    Las Pinas City, 1740, Philippines
  • Philippine General Hospital
    Manila City, 1000, Philippines
  • University of Santo Tomas Hospital
    Manila City, 1008, Philippines
  • St. Luke's Medical Center
    Quezon City, 1102, Philippines
  • Spitalul Clinic Sf Maria
    Bucharest, 011170, Romania
  • Spitalul Clinic Colentina
    Bucharest, 020125, Romania
  • Spitalul de Urgenta al Ministerului Administratiei si Internelor Prof. Dr. Dimitrie Gerota
    Bucharest, 020125, Romania
  • Spitalul Clinic Dr. Ion Cantacuzino
    Bucharest, 020475, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj-Napoca
    Cluj Napoca, 40006, Romania
  • State Institution Scientific Research Institute of Rheumatology
    Moscow, 115522, Russian Federation
  • St. Petersburg City Hospital (Rheumatology Center)
    St. Petersburg, 190068, Russian Federation
  • Academy of Post-Graduated Education
    St.-Petersburg, 191015, Russian Federation
  • St.-Petersburg Region Clinical Hospital
    St.-Petersburg, 194291, Russian Federation
  • Soloviev's City Clinical Hospital,
    Yaroslavl, 150003, Russian Federation
  • City Healthcare Institution Municipal Hospital NPZ,
    Yaroslavl, 190068, Russian Federation
  • Buddhist Tzu Chi General Hospital, Dalin
    Chia-Yi, 622, Taiwan
  • Buddhist Tzu Chi General Hospital - Hualien
    Haulien, 970, Taiwan
  • Chung-Ho Memorial Hospital, Kaohsiung Medical University
    Kaohsiung, 807, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung, 813, Taiwan
  • Chang Gung Memorial Hospital, Kaosiung
    Kaosiung, 833, Taiwan
  • Chang Gung Memorial Hospital-Keelung
    Keelung, 204, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Chang Gung Memorial Hospital, Linko
    Tau-Yuan County, 333, Taiwan
09

References and documents

Publications

  • Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6. PubMed 34741731 ↗
  • Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. PubMed 34628605 ↗
  • Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. PubMed 34531304 ↗
  • Rendas-Baum R, Baranwal N, Joshi AV, Park J, Kosinski M. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). J Patient Rep Outcomes. 2021 Apr 8;5(1):33. doi: 10.1186/s41687-021-00298-x. PubMed 33830377 ↗
  • Maslen T, Bruce IN, D'Cruz D, Ianosev M, Bass DL, Wilkinson C, Roth DA. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Sci Med. 2021 Feb;8(1):e000459. doi: 10.1136/lupus-2020-000459. PubMed 33568389 ↗
  • Gomez A, Hani Butrus F, Johansson P, Akerstrom E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021 Mar 2;60(3):1260-1272. doi: 10.1093/rheumatology/keaa453. PubMed 32918459 ↗
  • van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2020 Feb 1;59(2):281-291. doi: 10.1093/rheumatology/kez279. PubMed 31302695 ↗
  • Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014. PubMed 25396065 ↗
  • Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995. PubMed 23754628 ↗
  • Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE; BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014 May;73(5):838-44. doi: 10.1136/annrheumdis-2012-202865. Epub 2013 Mar 22. PubMed 23524886 ↗
  • Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. PubMed 23213069 ↗
  • van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15. PubMed 22337213 ↗
  • Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400. PubMed 22275291 ↗
  • Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4. PubMed 21296403 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of May 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years after primary completion. A results delay was requested in Sep 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 19, 2007
Start
May 2007
Primary completionActual
May 2009
CompletionActual
Mar 2010
Results delay requested
Sep 22, 2009
Results first posted
May 5, 2011
Last update
Dec 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424476
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 19, 2007
Start date
May 2007
Primary completion
May 2009
Completion
Mar 2010
Results posted
May 5, 2011
Last update
Dec 12, 2016

Study contacts

GSK Clinical Trials
study director · Human Genome Sciences Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion